Medigen Biotechnology Corp. (TPEX:3176)

Market Cap	4.00B
Revenue (ttm)	1.37B
Net Income (ttm)	-204.69M
Shares Out	139.31M
EPS (ttm)	-1.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,793
Average Volume	224,616
Open	29.15
Previous Close	28.70
Day's Range	28.40 - 29.15
52-Week Range	23.65 - 48.20
Beta	0.55
RSI	41.71
Earnings Date	Mar 28, 2025

About Medigen Biotechnology

Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cytotherapy, advanced nucleic acid testing, generic drugs, aesthetic medicine, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 3176

Financial Performance

In 2024, Medigen Biotechnology's revenue was 1.37 billion, an increase of 18.57% compared to the previous year's 1.16 billion. Losses were -204.69 million, -63.53% less than in 2023.